Operaciones Morphosys AG - MOR CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.09 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024161% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.020283% | ||||||||
| Horario tarifa nocturna | 22:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | EUR | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | Germany | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
MorphoSys AG ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 19.23 |
| Abrir* | 19 |
| Cambio de 1 año* | -31.56% |
| Rango del día* | 18.5 - 19 |
| Rango de 52 semanas | 11.81-28.31 |
| Volumen medio (10 días) | 108.88K |
| Volumen medio (3 meses) | 7.20M |
| Capitalización de mercado | 650.41M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 34.16M |
| Ingresos | 249.61M |
| EPS | -25.23 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.73 |
| Próxima fecha de resultados | Mar 15, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 18.87 | -0.42 | -2.18% | 19.29 | 19.29 | 18.26 |
| Feb 2, 2023 | 19.23 | 0.56 | 3.00% | 18.67 | 19.71 | 18.53 |
| Feb 1, 2023 | 18.43 | 0.26 | 1.43% | 18.17 | 18.73 | 18.14 |
| Jan 31, 2023 | 17.96 | 0.25 | 1.41% | 17.71 | 18.27 | 17.33 |
| Jan 30, 2023 | 17.96 | 0.09 | 0.50% | 17.87 | 18.22 | 17.75 |
| Jan 27, 2023 | 18.06 | 0.18 | 1.01% | 17.88 | 18.27 | 17.83 |
| Jan 26, 2023 | 17.96 | 0.14 | 0.79% | 17.82 | 18.18 | 17.70 |
| Jan 25, 2023 | 17.73 | 0.67 | 3.93% | 17.06 | 17.79 | 16.87 |
| Jan 24, 2023 | 17.00 | -0.45 | -2.58% | 17.45 | 17.69 | 16.88 |
| Jan 23, 2023 | 17.47 | 0.23 | 1.33% | 17.24 | 17.73 | 16.87 |
| Jan 20, 2023 | 16.94 | 0.70 | 4.31% | 16.24 | 17.23 | 16.05 |
| Jan 19, 2023 | 16.30 | -0.58 | -3.44% | 16.88 | 17.11 | 15.33 |
| Jan 18, 2023 | 17.04 | 0.19 | 1.13% | 16.85 | 17.27 | 16.57 |
| Jan 17, 2023 | 16.97 | 0.69 | 4.24% | 16.28 | 17.01 | 16.13 |
| Jan 16, 2023 | 16.47 | -0.07 | -0.42% | 16.54 | 16.82 | 16.17 |
| Jan 13, 2023 | 16.42 | 1.14 | 7.46% | 15.28 | 16.80 | 15.14 |
| Jan 12, 2023 | 15.12 | -0.38 | -2.45% | 15.50 | 15.68 | 14.89 |
| Jan 11, 2023 | 15.06 | 0.14 | 0.94% | 14.92 | 15.13 | 14.45 |
| Jan 10, 2023 | 14.63 | 0.38 | 2.67% | 14.25 | 14.94 | 14.14 |
| Jan 9, 2023 | 14.36 | 0.46 | 3.31% | 13.90 | 14.47 | 13.82 |
Morphosys AG Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos totales | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
| Ingresos | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
| Gastos totales de explotación | 109.685 | 134.398 | 136.584 | 178.803 | 301.039 | 685.818 |
| Gastos de venta/general/administración Gastos, total | 12.7561 | 15.7687 | 26.2302 | 55.7672 | 152.193 | 188.958 |
| Investigación y desarrollo | 82.1921 | 103.315 | 83.988 | 103.861 | 120.489 | 219.072 |
| Depreciation / Amortization | 3.764 | 4.03 | 3.75 | 3.458 | 7.255 | 7.557 |
| Gasto (ingreso) por intereses - Explotación neta | 0.208 | 0.359 | -0.22 | 0.18 | -18.237 | -13.584 |
| Gastos (ingresos) extraordinarios | 10.141 | 9.864 | 20.224 | 9.462 | 6.795 | 231.949 |
| Other Operating Expenses, Total | 0.62335 | 1.06219 | 0.81471 | 2.67494 | 13.4374 | 19.6719 |
| Ingresos de explotación | -59.941 | -67.6077 | -60.1411 | -107.048 | 26.6592 | -506.207 |
| Ingresos por intereses (gastos), netos No operativos | 0.132 | -0.768 | -0.237 | 1.354 | -35.614 | -81.632 |
| Otros, netos | -0.05516 | -0.41446 | -0.0987 | -0.8269 | 31.4468 | -3.21234 |
| Ingresos netos antes de impuestos | -59.8642 | -68.7901 | -60.4768 | -106.52 | 22.492 | -591.051 |
| Ingresos netos después de impuestos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Beneficio neto antes de partidas extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Ingresos netos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Ajuste por dilución | 0 | |||||
| Beneficio neto diluido | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Promedio ponderado de acciones diluidas | 26.4434 | 28.9476 | 31.3389 | 31.6112 | 33.1679 | 33.4011 |
| BPA diluido sin partidas extraordinarias | -2.28347 | -2.41217 | -1.79241 | -3.25879 | 2.95137 | -15.4025 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 | 0 |
| BPA normalizado diluido | -2.0342 | -2.19068 | -1.20385 | -3.04945 | 3.20838 | -10.8879 |
| Coste de los ingresos, total | 1.79663 | 3.4002 | 19.1071 | 32.1947 | ||
| Beneficio bruto | 74.6459 | 68.3551 | 308.591 | 147.417 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
| Ingresos | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
| Coste de los ingresos, total | 5.04798 | 10.1363 | 7.48222 | 9.52819 | 7.89249 |
| Beneficio bruto | 42.1416 | 28.0977 | 33.7625 | 43.4153 | 33.574 |
| Gastos totales de explotación | 76.4968 | 109.175 | 122.582 | 376.565 | 111.856 |
| Gastos de venta/general/administración Gastos, total | 38.4237 | 40.1544 | 51.347 | 50.7098 | 36.4825 |
| Investigación y desarrollo | 32.3171 | 40.5068 | 62.6749 | 87.0124 | 65.048 |
| Gasto (ingreso) por intereses - Explotación neta | -1.1 | 1.6 | -1.7 | -3.24 | |
| Gastos (ingresos) extraordinarios | -0.089 | 18.604 | 0.135 | 230.949 | 0.089 |
| Other Operating Expenses, Total | 1.89697 | -1.8263 | 0.94256 | 1.60571 | 2.34434 |
| Ingresos de explotación | -29.3072 | -70.9412 | -81.3369 | -323.621 | -70.3899 |
| Ingresos por intereses (gastos), netos No operativos | 7.1 | -7.7 | 4.2 | -95.782 | 3.4 |
| Otros, netos | -33.8928 | 113.038 | -76.8684 | 4.06089 | -55.6612 |
| Ingresos netos antes de impuestos | -56.0999 | 34.3967 | -154.005 | -415.342 | -122.651 |
| Ingresos netos después de impuestos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Beneficio neto antes de partidas extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Ingresos netos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Beneficio neto diluido | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
| Promedio ponderado de acciones diluidas | 32.7586 | 35.3712 | 34.1332 | 34.1487 | 34.1488 |
| BPA diluido sin partidas extraordinarias | -1.27015 | 0.59071 | -3.30388 | -11.1563 | -3.59167 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| BPA normalizado diluido | -1.27191 | 1.20559 | -3.30892 | -6.76036 | -3.58906 |
| Depreciation / Amortization | 1.7 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Activo Corriente | 308.056 | 340.681 | 388.905 | 303.693 | 1206.82 | 1132.97 |
| Efectivo e inversiones a corto plazo | 145.074 | 164.26 | 358.964 | 272.504 | 1090.32 | 993.664 |
| Cash | 73.929 | 76.589 | 45.4598 | 44.314 | 109.795 | 123.248 |
| Efectivo y Equivalentes | 1.25166 | 1.13313 | ||||
| Inversiones a corto plazo | 69.8938 | 86.5382 | 313.504 | 228.19 | 980.522 | 870.416 |
| Total deudores, neto | 149.682 | 163.833 | 20.7414 | 20.3408 | 89.8356 | 85.79 |
| Accounts Receivable - Trade, Net | 12.5967 | 11.2343 | 17.7329 | 15.0817 | 83.3543 | 75.911 |
| Total Inventory | 0.31037 | 0.30075 | 0.24516 | 0.28821 | 9.96266 | 20.7552 |
| Prepaid Expenses | 3.5 | 2.1 | 3.6 | 5.8 | 6.698 | 16.815 |
| Other Current Assets, Total | 9.48947 | 10.1868 | 5.35488 | 4.75963 | 10.0035 | 15.9454 |
| Total Assets | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
| Property/Plant/Equipment, Total - Net | 4.18911 | 3.52635 | 3.53071 | 47.8131 | 50.7415 | 49.5921 |
| Property/Plant/Equipment, Total - Gross | 19.047 | 19.836 | 18.597 | 63.9362 | 68.4008 | 69.8613 |
| Accumulated Depreciation, Total | -14.858 | -16.31 | -15.066 | -16.123 | -17.659 | -20.269 |
| Goodwill, Net | 7.3648 | 7.3648 | 3.67623 | 3.67623 | 1.61923 | 335.574 |
| Intangibles, Net | 60.5745 | 60.4821 | 43.6888 | 41.1221 | 69.3752 | 838.322 |
| Note Receivable - Long Term | 79.5212 | 0 | ||||
| Other Long Term Assets, Total | 3.89409 | 3.34429 | 2.98172 | 1.13603 | 134.373 | 199.796 |
| Total Current Liabilities | 38.3019 | 47.701 | 45.9233 | 61.5579 | 200.459 | 284.538 |
| Accounts Payable | 8.636 | 4.818 | 7.399 | 11.012 | 47.818 | 73.787 |
| Accrued Expenses | 22.838 | 36.408 | 36.53 | 44.971 | 79.2 | 113.055 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 6.82795 | 6.47504 | 1.99429 | 3.04744 | 69.9627 | 94.0353 |
| Total Liabilities | 48.1399 | 56.7272 | 50.3911 | 101.738 | 1038.19 | 2311.38 |
| Total Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 40.0416 | 314.724 | 322.13 |
| Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 0 | 272.76 | 282.785 |
| Deferred Income Tax | 7.42184 | 7.81126 | 3.50723 | 0 | 5.05747 | 22.0654 |
| Other Liabilities, Total | 2.19788 | 1.12709 | 0.88908 | 0.13809 | 517.951 | 1682.64 |
| Total Equity | 415.46 | 358.671 | 488.373 | 394.702 | 621.322 | 244.876 |
| Common Stock | 29.1598 | 29.4208 | 31.8396 | 31.958 | 32.89 | 34.2319 |
| Additional Paid-In Capital | 428.361 | 438.558 | 619.908 | 628.177 | 748.979 | 833.321 |
| Retained Earnings (Accumulated Deficit) | -27.5487 | -97.3751 | -152.766 | -255.78 | -157.889 | -672.349 |
| Treasury Stock - Common | -14.6482 | -11.827 | -10.3988 | -8.35725 | -4.86874 | -3.08505 |
| Unrealized Gain (Loss) | 0.1361 | -0.10548 | 0 | |||
| Total Liabilities & Shareholders’ Equity | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
| Total Common Shares Outstanding | 28.7638 | 29.1011 | 31.5585 | 31.7322 | 32.7586 | 34.1488 |
| Long Term Investments | 95.9811 | 98.999 | 196.588 | 0 | ||
| Other Equity, Total | -0.21089 | -1.29572 | 2.21142 | 52.7576 | ||
| Current Port. of LT Debt/Capital Leases | 2.52742 | 3.47855 | 3.66106 | |||
| Capital Lease Obligations | 40.0416 | 41.9638 | 39.3458 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 1257.38 | 1255.91 | 1294.76 | 1132.97 | 1013.44 |
| Efectivo e inversiones a corto plazo | 1122.26 | 1095.34 | 1155.19 | 993.664 | 855.47 |
| Cash | 109.586 | 297.335 | 249.767 | 123.248 | 108.873 |
| Inversiones a corto plazo | 1012.67 | 798.01 | 905.426 | 870.416 | 746.597 |
| Total deudores, neto | 104.173 | 108.192 | 82.0685 | 79.227 | 80.0492 |
| Accounts Receivable - Trade, Net | 101.298 | 97.1665 | 77.044 | 75.911 | 74.0944 |
| Total Inventory | 13.4 | 14.5171 | 13.2692 | 20.7552 | 20.89 |
| Prepaid Expenses | 17.5465 | 37.8531 | 44.2278 | 39.3234 | 57.0263 |
| Total Assets | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
| Property/Plant/Equipment, Total - Net | 49.9224 | 49.4239 | 51.9162 | 49.5921 | 48.6483 |
| Goodwill, Net | 1.61923 | 1.61923 | 570.959 | 335.574 | 342.343 |
| Intangibles, Net | 69.0447 | 79.0253 | 787.906 | 838.322 | 853.209 |
| Long Term Investments | 125.713 | 55.3782 | 0 | 0 | |
| Other Long Term Assets, Total | 146.23 | 136.061 | 178.404 | 199.796 | 199.721 |
| Total Current Liabilities | 202.263 | 204.554 | 259.123 | 284.538 | 238.959 |
| Payable/Accrued | 124.297 | 134.663 | 168.399 | 188.077 | 145.55 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 4.02894 | 3.68179 | 4.09169 | 3.66106 | 5.31028 |
| Other Current Liabilities, Total | 73.9369 | 66.2085 | 86.6328 | 92.8001 | 88.0983 |
| Total Liabilities | 1070.25 | 976.007 | 2286.69 | 2311.38 | 2315.62 |
| Total Long Term Debt | 316.63 | 318.27 | 320.184 | 322.13 | 322.835 |
| Long Term Debt | 275.193 | 277.677 | 280.218 | 282.785 | 284.218 |
| Capital Lease Obligations | 41.4369 | 40.5935 | 39.9657 | 39.3458 | 38.6175 |
| Deferred Income Tax | 2.32821 | 5.05747 | 23.8584 | 22.0654 | 22.5267 |
| Other Liabilities, Total | 549.032 | 448.126 | 1683.53 | 1682.64 | 1731.3 |
| Total Equity | 579.653 | 601.407 | 597.25 | 244.876 | 141.739 |
| Common Stock | 32.89 | 32.8925 | 34.2319 | 34.2319 | 34.2319 |
| Additional Paid-In Capital | 749.846 | 749.284 | 832.584 | 833.321 | 833.376 |
| Retained Earnings (Accumulated Deficit) | -199.497 | -178.603 | -291.375 | -672.349 | -795 |
| Treasury Stock - Common | -4.86874 | -3.78304 | -3.37201 | -3.08505 | -3.08505 |
| Other Equity, Total | 1.2836 | 1.61683 | 25.1808 | 52.7576 | 72.2164 |
| Total Liabilities & Shareholders’ Equity | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
| Total Common Shares Outstanding | 32.7586 | 32.7905 | 34.141 | 34.1488 | 34.1488 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
| Efectivo de actividades de explotación | -46.6157 | -38.4459 | -32.7813 | -81.0702 | 34.5197 | -481.445 |
| Efectivo de actividades de explotación | 3.76381 | 4.02895 | 3.75026 | 6.24516 | 8.32956 | 10.091 |
| Partidas no monetarias | -4.4191 | -3.29514 | 24.182 | -2.07177 | -83.4769 | 200.528 |
| Cash Taxes Paid | 0.54038 | 1.86198 | 0.03384 | 0.06256 | 0.30397 | 64.6096 |
| Intereses pagados en efectivo | 0.00182 | 0 | 0.13427 | 1.01132 | 1.43149 | 4.74485 |
| Cambios en el capital circulante | 14.4224 | 30.6468 | -4.54142 | 17.7704 | 11.7764 | -177.604 |
| Efectivo de actividades de inversión | -80.786 | 32.9325 | -177.751 | 79.4841 | -879.623 | -831.01 |
| Gastos de capital | -2.91349 | -13.1489 | -2.46532 | -3.66564 | -49.3365 | -26.1562 |
| Otras partidas de flujo de caja de inversión, total | -77.8726 | 46.0813 | -175.285 | 83.1497 | -830.286 | -804.854 |
| Efectivo procedente de actividades de financiación | 110.403 | 8.17382 | 179.462 | 0.35324 | 907.186 | 1322.92 |
| Elementos de flujo de caja de financiación | -2.78047 | -0.01553 | -15.1726 | -1.01132 | 508.655 | 1241.08 |
| Emisión (retiro) de acciones, neto | 113.19 | 0 | 193.614 | 0 | 80.5985 | 84.73 |
| Emisión (amortización) de deuda, neta | -0.00671 | 8.18935 | 1.02085 | 1.36456 | 317.933 | -2.88511 |
| Efectos del cambio de divisas | 0 | -0.05946 | 0.08712 | 3.39766 | 2.98531 | |
| Variación neta de la tesorería | -16.999 | 2.66047 | -31.1293 | -1.14579 | 65.4806 | 13.4536 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -41.6082 | -20.714 | -133.486 | -514.46 | -122.651 |
| Cash From Operating Activities | -42.2207 | -131.585 | -323.96 | -481.445 | -143.812 |
| Cash From Operating Activities | 2.31626 | 4.65405 | 7.3535 | 10.091 | 2.57174 |
| Non-Cash Items | 16.223 | -79.0437 | -68.6942 | 200.528 | 36.1088 |
| Cash Taxes Paid | 0.07992 | 0.08336 | 1.31085 | 64.6096 | 0.07782 |
| Cash Interest Paid | 0.53635 | 2.21944 | 2.91855 | 4.74485 | 0.42117 |
| Changes in Working Capital | -19.1517 | -36.4816 | -129.134 | -177.604 | -59.8415 |
| Cash From Investing Activities | 33.1924 | 292.728 | -850.081 | -831.01 | 115.187 |
| Capital Expenditures | -0.82796 | -12.4208 | -17.0882 | -26.1562 | -1.1706 |
| Other Investing Cash Flow Items, Total | 34.0204 | 305.149 | -832.993 | -804.854 | 116.358 |
| Cash From Financing Activities | 11.0258 | 27.857 | 1317 | 1322.92 | 13.7736 |
| Financing Cash Flow Items | 11.8149 | 29.2795 | 1234.36 | 1241.08 | 14.5762 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | 84.7314 | 84.73 | |
| Issuance (Retirement) of Debt, Net | -0.78905 | -1.42251 | -2.09185 | -2.88511 | -0.80261 |
| Foreign Exchange Effects | -2.20631 | -1.45931 | -2.98555 | 2.98531 | 0.47603 |
| Net Change in Cash | -0.20874 | 187.54 | 139.973 | 13.4536 | -14.3749 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 5.743 | 1965924 | 661108 | 2023-01-12 | LOW |
| Armistice Capital LLC | Hedge Fund | 5.1648 | 1768000 | 732000 | 2023-01-10 | HIGH |
| Goldman Sachs Asset Management, L.P. | Investment Advisor | 4.7869 | 1638637 | -39276 | 2023-01-18 | LOW |
| T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 3.942 | 1349436 | -250322 | 2022-02-16 | MED |
| RP Management, LLC | Private Equity | 3.9073 | 1337552 | 1337552 | 2021-07-29 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 3.6317 | 1243209 | 376568 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.2165 | 1101057 | -84879 | 2022-10-06 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 3.2134 | 1100000 | 1100000 | 2022-12-02 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 2.9531 | 1010913 | 10045 | 2021-09-20 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.819 | 965001 | 11213 | 2022-12-31 | LOW |
| Baillie Gifford & Co. | Investment Advisor | 2.4401 | 835292 | -1213122 | 2022-12-16 | LOW |
| Morgan Stanley | Corporation | 1.5309 | 524062 | 524062 | 2022-11-21 | LOW |
| Invesco Advisers, Inc. | Investment Advisor | 1.3857 | 474360 | 0 | 2022-12-31 | LOW |
| Bank of America Corp | Corporation | 1.2942 | 443038 | 128097 | 2022-12-22 | MED |
| AMG Fondsverwaltung AG | Investment Advisor | 1.2112 | 414617 | 67321 | 2022-04-30 | LOW |
| Eleva Capital SAS | Investment Advisor | 1.1824 | 404760 | 404760 | 2022-10-31 | HIGH |
| Lupus alpha Asset Management AG | Investment Advisor/Hedge Fund | 1.1072 | 379000 | -52000 | 2022-10-31 | MED |
| Mirova | Investment Advisor | 1.0159 | 347778 | -945 | 2022-11-30 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 0.9603 | 328727 | 0 | 2022-12-31 | HIGH |
| Macquarie Investment Management | Investment Advisor | 0.8764 | 300000 | 0 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group +485000+
Traders
65000+
Clientes activos mensualmente
$48000000+
Volumen mensual de inversión
$28000000+
Pruébalo ahora Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Comisión de la operación
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Apalancamiento
20:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Morphosys Company profile
Sobre MorphoSys AG
MorphoSys AG desarrolla y comercializa anticuerpos para aplicaciones terapéuticas. La empresa desarrolla fármacos utilizando su propia investigación y desarrollo, así como en cooperación con socios farmacéuticos y biotecnológicos. Los segmentos operativos de la empresa incluyen el Desarrollo Propio y el Descubrimiento Asociado. En el segmento de Desarrollo Propio, desarrolla anticuerpos y péptidos terapéuticos en el ámbito de las enfermedades inflamatorias y la oncología. En el segmento Partnered Discovery, la empresa aplica tecnologías para la investigación, el desarrollo y la optimización de anticuerpos terapéuticos como candidatos a fármacos. La empresa desarrolla nuevos tratamientos para pacientes que padecen enfermedades graves. Sus tecnologías incluyen HuCAL, que es una colección de anticuerpos totalmente humanos y un sistema para su optimización; Ylanthia, que es una biblioteca de anticuerpos en formato Fab, y Slonomics, una tecnología automatizada de síntesis y modificación de genes para la generación de bibliotecas de genes en un proceso controlado.
| Industry: | Biotechnology & Medical Research (NEC) |
Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 485.000 traders de todo el mundo que eligen operar con Capital.com